Senologie - Zeitschrift für Mammadiagnostik und -therapie 2014; 11 - A30
DOI: 10.1055/s-0034-1375389

Comparison of Acute Toxicity between Boost With MammoSite and Boost with External Photon Beam in the adjuvant radiotherapy of Breast Cancer after Lumpectomy.

K Fakhrian 1, A Gitt 2, H Hermani 2, H Böse-Ribeiro 3, D Drüppel 4, HY Ergönenç 4, K Fakhrian 5
  • 1Marienhospital Herne, Ruhr-Universität Bochum, Herne, Deutschland
  • 2Marienhospital Herne, Ruhr-Universität Bochum, Klinik für Strahlentherapie, Herne, Deutschland
  • 3Sankt Josef Hospital Bochum, Ruhr-Universität Bochum, Bochum, Deutschland
  • 4Brustzentrum Bochum-Herne, St. Anna Hospital Herne, Herne, Deutschland
  • 5Klinik für Strahlentherapie und Radio-Onkologie-Marienhospital Herne, Ruhr-Universität Bochum, Herne, Deutschland


To compare rates of acute Toxicity (AT) between patients treated with MammoSite Boost + Whole Breast Irradiation (WBI) with patients treated with WBI + Boost with Photon External Beam Radiotherapy (B-EBRT) at a single center.

Methods and Materials:

A total of 150 women underwent Mammosite Boost irradiation + WBI after lumpectomy and a total of 342 women underwent WBI + B-EBRT between 2011 – 2013 at our department. Included were patients who were followed up at least for 3 months. A matched-pair analysis was performed based on age, receipt of hormonal therapy, chemotherapy, nodal status, and tumor size (132 patients per arm). Rates of RTOG acute toxicities ≥ III° were then analyzed for each group.


After the match, no differences in patient characteristics were noted when tumor size was evaluated as a continuous variable. Except for a higher rate of seroma formation 55% vs. 7% p = 0.001 and radiodermatits 1% vs. 5% (p = 0.018), we observed no significant difference between 2 groups with regard of acute toxicity.


Although the rate of seroma formation is significantly higher in patients who underwent Mammosite Boost, the lower rate of radiodermatitis ≥ III° in these patients fails to confirm other retrospective claims analyses that have suggested higher rates of acute toxicity for MammoSite treatment.